Lupus Nephritis

Chapter

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by the production of multiple autoantibodies, a striking female predominance, and the frequent development of immune complex-mediated glomerulonephritis.

Keywords

Corticosteroid Anemia Flare Glucocorticoid Cyclosporine 

Sources

  1. 1.
    Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med. 1987;83:877.PubMedCrossRefGoogle Scholar
  2. 2.
    Austin 3rd HA, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544.PubMedCrossRefGoogle Scholar
  3. 3.
    Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14:890.PubMedCrossRefGoogle Scholar
  4. 4.
    Schwartz MM, Lan SP, Bernstein J, et al. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int. 1992;42:743.PubMedCrossRefGoogle Scholar
  5. 5.
    Esdaile JM, Joseph L, MacKenzie T, et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994;21:2046.PubMedGoogle Scholar
  6. 6.
    Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33:1563.PubMedGoogle Scholar
  7. 7.
    Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;35:904.PubMedCrossRefGoogle Scholar
  8. 8.
    Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46.PubMedCrossRefGoogle Scholar
  9. 9.
    Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005;14:265.PubMedCrossRefGoogle Scholar
  10. 10.
    Korbet SM, Schwartz MM, Evans J, Lewis EJ, Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18:244.PubMedCrossRefGoogle Scholar
  11. 11.
    Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995.PubMedCrossRefGoogle Scholar
  12. 12.
    Moroni G, Quaglini S, Maccario M, et al. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996;50:2047.PubMedCrossRefGoogle Scholar
  13. 13.
    Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997;51:1188.PubMedCrossRefGoogle Scholar
  14. 14.
    Alarcón GS, McGwin Jr G, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum. 2001;45:191.PubMedCrossRefGoogle Scholar
  15. 15.
    Adler M, Chambers S, Edwards C, et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford). 2006;45:1144.CrossRefGoogle Scholar
  16. 16.
    Valeri A, Radhakrishnan J, Estes D, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol. 1994;42:71.PubMedGoogle Scholar
  17. 17.
    Cheigh JS, Kim H, Stenzel KH, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis. 1990;16:189.PubMedGoogle Scholar
  18. 18.
    Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103.PubMedCrossRefGoogle Scholar
  19. 19.
    Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971.PubMedCrossRefGoogle Scholar
  20. 20.
    Gourley MF, Austin 3rd HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549.PubMedGoogle Scholar
  21. 21.
    Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248.PubMedGoogle Scholar
  22. 22.
    Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121.PubMedCrossRefGoogle Scholar
  23. 23.
    Yee CS, Gordon C, Dostal C, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis. 2004;63:525.PubMedCrossRefGoogle Scholar
  24. 24.
    Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Arthritis Rheum. 2010;69:61.Google Scholar
  25. 25.
    Houssiau FA, Vasconcelos C, D’Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50:3934.PubMedCrossRefGoogle Scholar
  26. 26.
    Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010;49:128.PubMedCrossRefGoogle Scholar
  27. 27.
    Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89:227.CrossRefGoogle Scholar
  28. 28.
    Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076.PubMedCrossRefGoogle Scholar
  29. 29.
    Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992;326:1373.PubMedCrossRefGoogle Scholar
  30. 30.
    Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000;57:258.PubMedCrossRefGoogle Scholar
  31. 31.
    Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61:1502.PubMedCrossRefGoogle Scholar
  32. 32.
    Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006;21:1541.PubMedCrossRefGoogle Scholar
  33. 33.
    Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant. 2006;21:1465.PubMedCrossRefGoogle Scholar
  34. 34.
    Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006;54:421–32.CrossRefGoogle Scholar
  35. 35.
    Houssiau FA, D-Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Falk RJ, Schur PH, Appel GB. Therapy of diffuse or focal proliferative lupus nephritis. In: Basow DS, editor. UpToDate. Waltham: UpToDate; 2011.Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Division of Rheumatology and ImmunologyUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations